Применение каннабиноидов в медицине и офтальмологии
Аннотация
В обзоре дается описание терминологии, истории, законодательного регулирования, фармакодинамики и фармакокинетики каннабиноидов, а также результаты исследований их применения в терапии онкологических заболеваний, связанной с химиотерапией симптоматики (интенсивный болевой синдром, тошнота) и неврологических заболеваний (рассеянный склероз, болезнь Альцгеймера, шизофрения). Приведены результаты исследований системного применения каннабиноидов по снижению внутриглазного давления у здоровых лиц и пациентов с различными формами глаукомы. Описаны данные последних исследований взаимосвязи эндоканнабиноидной системы и регуляции тока внутриглазной жидкости, а также сосудорасширяющего и нейропротекторного эффектов. Приведены официальные позиции международных офтальмологических сообществ, не рекомендующих применение каннабиноидов в терапии глаукомы по причине краткосрочного гипотензивного эффекта и низкого системного уровня безопасности.
Ключевые слова
каннабис,
каннабиноиды,
рецепторы,
глаукома,
внутриглазное давление,
нейропротекция,
cannabis,
cannabinoids,
receptors,
glaucoma,
intraocular pressure,
neuroprotection
Об авторах
Сергей Юрьевич Петров
ФГБНУ «НИИ глазных болезней»
Россия
Россия
С. В. Вострухин
ФГБНУ «НИИ глазных болезней»
Россия
Россия
Д. М. Сафонова
ФГБНУ «НИИ глазных болезней»
Россия
Россия
Список литературы
1. Obembe S.B. Practical skills and clinical management of alcoholism and drug addiction. 1st ed. London; Waltham, MA: Elsevier; 2012, 104 p.
2. Wikipedia: Marijuana. Available from: http://en.wikipedia.org/wiki/Cannabis_%28drug%29.
3. Rudgley R. Lost civilisations of the Stone Age. London: Century; 1998.
4. Grinspoon L., Bakalar J.B. Marihuana, the forbidden medicine. Rev. and exp. ed. New Haven: Yale University Press; 1997. xv, 296 p.
5. Castle D.J., Murray R., D’Souza D.C. Marijuana and madness. 2nd ed. Cambridge; New York: Cambridge University Press; 2012. xi, 240 p., 248 p. of col. plates p.
6. The Economist’s country of the year. The Economist. Dec 21st 2013.
7. The Marlboro of marijuana. The Economist. Nov 8th 2014.
8. California ballot pamphlet: general election. Medical use of marijuana. Initiative statute. 1996. Available from: http://vote96.sos.ca.gov/bp/215.htm.
9. Bradford A. What is THC? LiveScience. April 7, 2015. Available at: http://www.livescience.com/24553-what-is-thc.html. Accessed April 9, 2015.
10. National Cancer Institute. Cannabis and cannabinoids (PDQ). Updated December 17, 2014. Available at: http://www.cancer.gov/cancertopics/pdq/cam/cannabis/healthprofessional. Accessed April 9, 2015.
11. National Institute on Drug Abuse. Drugfacts: is marijuana medicine? Rev December 2014. Available at: http://www.drugabuse.gov/publications/drugfacts/marijuana-medicine. Accessed April 6, 2015.
12. Vaida B. Medical marijuana: what the research shows. WebMD. Available at: http://www.webmd.com/news/breaking-news/marijuana-on-main-street/medical-marijuana-research-web. Accessed April 9, 2015.
13. Borrelli F., Pagano E., Romano B., Panzera S. et al. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis 2014; 35(12): 2787-2797. doi: 10.1093/carcin/bgu205.
14. Caffarel M.M., Andradas C., Perez-Gomez E., Guzman M., Sanchez C. Cannabinoids: a new hope for breast cancer therapy? Cancer Treatment Reviews 2012; 38(7): 911-918. doi: 10.1016/j. ctrv.2012.06.005.
15. Takeda S., Okajima S., Miyoshi H., Yoshida K. et al. Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration. Toxicology Letters 2012; 214(3): 314-319. doi: 10.1016/j.toxlet.2012.08.029.
16. Nabissi M., Morelli M.B., Santoni M., Santoni G. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis 2013; 34(1): 48-57. doi: 10.1093/carcin/bgs328.
17. Cridge B.J., Rosengren R.J. Critical appraisal of the potential use of cannabinoids in cancer management. Cancer Management and Research 2013; 5: 301-313. doi: 10.2147/CMAR.S36105.
18. Salazar M., Lorente M., Garcia-Taboada E., Perez Gomez E. et al. Loss of Tribbles pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO inactivation. Cell Death and Differentiation 2015; 22(1): 131-144. doi: 10.1038/cdd.2014.133.
19. Velasco G., Sanchez C., Guzman M. Towards the use of cannabinoids as antitumour agents. Nature Reviews Cancer 2012; 12(6): 436-444. doi: 10.1038/nrc3247.
20. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): antiemesis. V.I.2015. Available at: http://www.nccn.org/professionals/physician_gls/ pdf/antiemesis.pdf. Accessed April 10, 2015.
21. Boychuk D.G., Goddard G., Mauro G., Orellana M.F. The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review. J Oral Facial Pain and Headache 2015; 29(1): 7-14. doi: 10.11607/ofph.1274.
22. Kahan M., Srivastava A., Spithoff S., Bromley L. Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations. Canadian Family Physician. Medecin De Famille Canadien 2014; 60(12): 1083-1090.
23. Moulin D., Boulanger A., Clark A.J., Clarke H. et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Research & Management: the journal of the Canadian Pain Society = Journal de la societe canadienne pour le traitement de la douleur 2014; 19(6): 328-335.
24. Abrams D.I., Couey P., Shade S.B., Kelly M.E., Benowitz N.L. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther 2011; 90(6): 844-851. doi: 10.1038/clpt.2011.188.
25. Abrams D.I., Guzman M. Cannabis in cancer care. Clin Pharmacol Ther 2015. doi: 10.1002/cpt.108.
26. Bar-Sela G., Vorobeichik M., Drawsheh S., Omer A., Goldberg V., Muller E. The medical necessity for medicinal cannabis: prospective, observational study evaluating the treatment in cancer patients on supportive or palliative care. Evidence-based complementary and alternative medicine: eCAM 2013; 510392. doi: 10.1155/2013/510392.
27. Koppel B.S., Brust J.C., Fife T., Bronstein J. et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014; 82(17): 1556-1563. doi: 10.1212/WNL.0000000000000363.
28. GW Pharmaceuticals. Epidiolex. Available at: http://www.gwpharm.com/Epidiolex.aspx. Accessed April 9, 2015.
29. GW Pharmaceuticals. Sativex. Available at: http://www.gwpharm.com/sativex.aspx. Accessed April 9, 2015
30. Hepler R.S., Frank I.R. Marihuana smoking and intraocular pressure. JAMA 1971; 217(10): 1392.
31. Lockhart A.B., West M.E., Lowe H.I. The potential use of Cannabis sativa in ophthalmology. The West Indian Medical J 1977; 26(2): 66-70.
32. Cuendet J.F., Shapiro D., Calanca A., Faggioni R., Ducrey N. Action of delta-9-tetrahydrocannabinol on ophthalmotonus. Ophthalmologica Journal international d’ophtalmologie International journal of ophthalmology Zeitschrift fur Augenheilkunde. 1975; 172(2-3): 122-127.
33. Flom M.C., Adams A.J., Jones R.T. Marijuana smoking and reduced pressure in human eyes: drug action or epiphenomenon? Invest Ophthalmol 1975; 14(1): 52-55.
34. Merritt J.C., Crawford W.J., Alexander P.C., Anduze A.L., Gelbart S.S. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 1980; 87(3): 222-228.
35. Green K. Marijuana smoking vs cannabinoids for glaucoma therapy. Arch Ophthalmol 1998; 116(11): 1433-1437.
36. National Institutes of Health. Report on the Workshop on the Medical Utility of Marijuana. Rockville, MD: PHS; 1997.
37. Flach A.J. Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. Transactions of the American Ophthalmological Society 2002; 100: 215-222; discussion 222-214.
38. Jarvinen T., Pate D.W., Laine K. Cannabinoids in the treatment of glaucoma. Pharmacology & Therapeutics 2002; 95(2): 203-220.
39. Nadolska K., Gos R. [Possibilities of applying cannabinoids’ in the treatment of glaucoma]. Klinika Oczna 2008; 110(7-9): 314-317.
40. Nucci C., Bari M., Spano A., Corasaniti M. et al. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection. Prog Brain Res 2008; 173: 451-464. doi: 10.1016/S0079-6123(08)01131-X.
41. Buys Y.M., Rafuse P.E. Canadian Ophthalmological Society policy statement on the medical use of marijuana for glaucoma. Can J Ophthalmol Journal canadien d’ophtalmologie 2010; 45(4): 324-326. doi: 10.3129/i10-069.
42. Jampel H. American glaucoma society position statement: marijuana and the treatment of glaucoma. J Glaucoma 2010; 19(2): 75-76. doi: 10.1097/IJG.0b013e3181d12e39.
43. Kaufman P.L. Marijuana and glaucoma. Arch Ophthalmol 1998; 116(11): 1512-1513.
44. Complementary therapy assessment marijuana in the treatment of glaucoma, American Academy of Ophthalmology, June 2014.
Рецензия
Для цитирования:
Петров С.Ю., Вострухин С.В., Сафонова Д.М. Применение каннабиноидов в медицине и офтальмологии. Национальный журнал Глаукома. 2016;15(4):95-100.
For citation:
Petrov S.Yu., Vostrukhin S.V., Safonova D.M. The use of cannabinoids in medicine and ophthalmology. National Journal glaucoma. 2016;15(4):95-100. (In Russ.)
Просмотров: 1182
Послать статью по эл. почте 